miltefosine has been researched along with Animal Mammary Carcinoma in 2 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duijsings, D | 1 |
| Houweling, M | 1 |
| Vaandrager, AB | 1 |
| Mol, JA | 1 |
| Teerds, KJ | 1 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Schönenberger, H | 1 |
| Engel, J | 1 |
2 other studies available for miltefosine and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Hexadecylphosphocholine causes rapid cell death in canine mammary tumour cells.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; CHO Cells; Cricetinae; Dogs; Dose-Resp | 2004 |
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug | 1993 |